Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 26.09 percent increase over losses of $(0.23) per share from the same period last year. The company reported $225.000 thousand in sales this quarter.